LRLisa E. L. Romano

Lisa E. L. Romano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lisa E. L. Romano has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metformin decreases RAN proteins, rescues splicing abnormalities and improves behavioral phenotypes in SCA8 BAC mice

    by Lisa E.L Romano, Setsuki Tsukagoshi, Emily E. Davey-Osuch, Ramadan Ajredini, Kamat Manasi, Tala V.R. Ortiz, Eduardo Rijos, Nathan J. Bourgon, S. Elaine Ames, Timothy J. Garrett, et al.

    Spinocerebellar ataxia type 8 is one member of a larger group of dominantly inherited, debilitating neurological diseases caused by CTG*CAG expansions for which there are no effective disease-targeting treatments. RAN translation, which was discovered in SCA8, has previously been shown to occur across CAG and CUG expansion transcripts, making treatments that work for SCA8 potentially relevant to a much broader group of diseases, including SCA1, 2, 3, 6, 7, 12, Huntington’s Disease (HD) Fuch’s endothelial corneal dystrophy (FECD), and myotonic dystrophy type 1 (DM1). The FDA-approved drug, metformin, has been previously shown to reduce RAN protein levels in cells overexpressing SCA8 CAG repeats. Here we show, using SCA8 BAC transgenic mice, that metformin treatment improves ambulatory performance, including rotarod, DigiGait, and open field measures. At the molecular level, metformin-treated mice show reduced RAN protein levels and improved splicing abnormalities without changing the levels of the expanded RNAs. Metformin-treated mice also show decreased neuroinflammation with reduced levels of astrogliosis and reduced numbers of activated microglia. Taken together, these data provide strong support for testing FDA-approved metformin in clinical trials for SCA8 and potentially the broader group of CAG*CTG repeat expansion disorders. One Sentence Summary: Metformin improves behavior, neuropathological and molecular phenotypes in SCA8 BAC transgenic mice.

  • Open Access

    CASP8 intronic expansion identified by poly-glycine-arginine pathology increases Alzheimer’s disease risk

    by Lien Nguyen, Ramadan Ajredini, Shu Guo, Lisa E. L. Romano, Rodrigo F. Tomas, Logan R. Bell, Paul T. Ranum, Tao Zu, Monica Bañez Coronel, Chase P. Kelley, et al.

    Alzheimer’s disease (AD) affects more than 10% of the population ≥65 y of age, but the underlying biological risks of most AD cases are unclear. We show anti-poly-glycine-arginine (a-polyGR) positive aggregates frequently accumulate in sporadic AD autopsy brains (45/80 cases). We hypothesize that these aggregates are caused by one or more polyGR-encoding repeat expansion mutations. We developed a CRISPR/deactivated-Cas9 enrichment strategy to identify candidate GR-encoding repeat expansion mutations directly from genomic DNA isolated from a-polyGR(+) AD cases. Using this approach, we isolated an interrupted (GGGAGA) n intronic expansion within a SINE-VNTR-Alu element in CASP8 ( CASP8 -GGGAGA EXP ). Immunostaining using a-polyGR and locus-specific C-terminal antibodies demonstrate that the CASP8 -GGGAGA EXP expresses hybrid poly(GR)n(GE)n(RE)n proteins that accumulate in CASP8 -GGGAGA EXP (+) AD brains. In cells, expression of CASP8 -GGGAGA EXP minigenes leads to increased p-Tau (Ser202/Thr205) levels. Consistent with other types of repeat-associated non-AUG (RAN) proteins, poly(GR)n(GE)n(RE)n protein levels are increased by stress. Additionally, levels of these stress-induced proteins are reduced by metformin. Association studies show specific aggregate promoting interrupted CASP8 -GGGAGA EXP sequence variants found in ~3.6% of controls and 7.5% AD cases increase AD risk [ CASP8 -GGGAGA-AD-R1; OR 2.2, 95% CI (1.5185 to 3.1896), P = 3.1 × 10 −5 ]. Cells transfected with a high-risk CASP8 -GGGAGA-AD-R1 variant show increased toxicity and increased levels of poly(GR)n(GE)n(RE)n aggregates. Taken together, these data identify polyGR(+) aggregates as a frequent and unexpected type of brain pathology in AD and CASP8 -GGGAGA-AD-R1 alleles as a relatively common AD risk factor. Taken together, these data support a model in which CASP8 -GGGAGA EXP alleles combined with stress increase AD risk.


  • Open Access

    N-SREBP2 Provides a Mechanism for Dynamic Control of Cellular Cholesterol Homeostasis

    by Tozen Ozkan-Nikitaras, Dominika J. Grzesik, Lisa E. L. Romano, J. P. Chapple, Peter J. King, Carol C. Shoulders

    Cholesterol is required to maintain the functional integrity of cellular membrane systems and signalling pathways, but its supply must be closely and dynamically regulated because excess cholesterol is toxic. Sterol regulatory element-binding protein 2 (SREBP2) and the ER-resident protein HMG-CoA reductase (HMGCR) are key regulators of cholesterol biosynthesis. Here, we assessed the mechanistic aspects of their regulation in hepatic cells. Unexpectedly, we found that the transcriptionally active fragment of SREBP2 (N-SREBP2) was produced constitutively. Moreover, in the absence of an exogenous cholesterol supply, nuclear N-SREBP2 became resistant to proteasome-mediated degradation. This resistance was paired with increased occupancy at the HMGCR promoter and HMGCR expression. Inhibiting nuclear N-SREBP2 degradation did not increase HMGCR RNA levels; this increase required cholesterol depletion. Our findings, combined with previous physiological and biophysical investigations, suggest a new model of SREBP2-mediated regulation of cholesterol biosynthesis in the organ that handles large and rapid fluctuations in the dietary supply of this key lipid. Specifically, in the nucleus, cholesterol and the ubiquitin–proteasome system provide a short-loop system that modulates the rate of cholesterol biosynthesis via regulation of nuclear N-SREBP2 turnover and HMGCR expression. Our findings have important implications for maintaining cellular cholesterol homeostasis and lowering blood cholesterol via the SREBP2-HMGCR axis.